Can a One-Time Gene Therapy Permanently Lower LDL Cholesterol?

The New England Journal of Medicine recently published some pretty amazing data on an emerging treatment approach. 

Researchers tested a one-time infusion - a single IV drip, given once - that edits a gene in the liver responsible for driving up LDL cholesterol. In the trial, that single treatment lowered LDL by up to 62% and the effects were still holding nearly a year later. No daily pills. No ongoing injections. One treatment.

That's not science fiction. That's a Phase 1 clinical trial published in the most prestigious medical journal in the world.

Now, before you start wondering if you can get this at your next appointment, let me give you the honest picture. And then I want to tell you why this research, exciting as it is, actually reinforces something you can do right now.

First, Some Background

LDL is removed from the bloodstream by attaching to receptors on cells.  The more LDL receptors there are, the more active they are, the more efficient the LDL removal process, and the less LDL is left floating around in your bloodstream.  LDL receptor levels are heavily influenced by an enzyme called PCSK9.  When PCSK9 levels are high, LDL receptor levels are low, leading to high circulating levels of LDL cholesterol.  The opposite is also true: People with a genetic deficiency of PCSK9 have very low circulating LDL levels over their entire lifetimes and typically don’t develop cardiovascular disease.  

Newer injectable drugs like Repatha®, Praluent® and Leqvio® all lower PCSK9 levels leading to higher LDL receptor numbers, often yielding dramatic LDL reductions.  People typically self-inject Repatha® and Praluent® at home, once every couple of weeks.  Leqvio® is injected every 6 months at a physician’s office.  Because they are new and expensive, insurers approve them only in those individuals who either can’t tolerate statins or are not at goal despite maximum tolerated statin doses.

What the Latest Trial was About

The therapy tested is called VERVE-102. VERVE-102 is a gene-based approach attempting to give that same low PCSK9 protection to people who weren't born with it. An edit to our genetic makeup. The molecular biology equivalent of a pencil erasing a few characters of code that have been driving a decades-long problem. 

The early results are genuinely impressive. Marked LDL reduction that appears to hold over time.  But this is still early-stage research. The trial enrolled a small number of patients with a specific inherited cholesterol condition - not the general public - and we don't yet have long-term data on hard outcomes like heart attacks and strokes. That evidence will take years to accumulate. This isn't coming to your doctor's office anytime soon.

We also don’t have any data on what we might be breaking by altering our DNA.  Our genetic code is not something we should mess with lightly.

So Why Am I Writing About This?

Because I think the science illuminates something important about how heart disease actually works.

The whole logic behind targeting PCSK9 - genetically or otherwise - is that lower LDL, sustained over time, means less damage to your arteries. That's not a new idea. After all, this is the thinking behind the latest cholesterol lowering guidelines that have pushed the definition of “normal” for LDL to 100 mg/dL or less.  

Lower for Longer Today… and Tomorrow

Lower LDL, sustained over time is also what happens when you consistently eat foods that your body is designed to process well. Soluble fiber (found in oats, beans, flaxseed) reduces LDL by pulling cholesterol out before it's absorbed. Plant sterols, which occur naturally in nuts and seeds, compete with cholesterol for absorption. Omega-3 fatty acids lower triglycerides and calm inflammation in blood vessel walls. These aren't exotic interventions. They're breakfast.

Done consistently, a diet built around these ingredients can produce meaningful LDL reductions - not as dramatic as gene editing, but real, measurable, and cumulative over a lifetime. And unlike a Phase 1 drug trial, this approach is available to you today, with no side effects and no waitlist.

The other critical point to make is that even if LDL is managed beautifully, because you are genetically blessed or because you’re on the perfect combination of the best available treatments, the importance of nutrition does not fade.  Because, when it comes to health, there is simply no amount of medication or genetic blessings that can overcome the wrong diet.  It’s what I saw in my own practice and what put me on the road to start Step One Foods.

What This All Means for You

If you have a family history of very high cholesterol that can't be controlled with standard medications, this research is genuinely worth watching. Ask your doctor whether familial hypercholesterolemia applies to you. Therapies like this one are being developed with patients exactly like that in mind.

For everyone else: the most powerful thing you can do for your heart right now is not waiting for the next breakthrough. It's the consistent, everyday choices that lower your LDL burden slowly and steadily - year after year, before symptoms ever appear.

Science keeps finding new ways to target the same underlying biology. Food got there first.  And food will always be... step one.